# A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

> **NCT00552617** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Placebo
- **DRUG:** Rocuronium
- **DRUG:** Vecuronium

## Key facts

- **NCT ID:** NCT00552617
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-20
- **Primary completion:** 2006-08-31
- **Final completion:** 2006-08-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552617, "A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00552617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*